Multiple Myeloma is a hematological malignancy characterized by the proliferation of clonal plasma cells and associated with severe clinical manifestations. Despite advancements in diagnosis and management, Multiple Myeloma remains incurable, necessitating further research into more effective therapies.
Aim:
The primary objective of this review is to provide an informative and critical summary of the Multiple Myeloma microenvironment, and emerging revolutionary therapeutic approaches with potential combination therapy to improve the quality of life for Multiple Myeloma patients.
Emerging approaches:
Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have shown improvements in immune response against Multiple Myeloma. ICIs target inhibitory pathways such as PD-1/PD-L1 and CTLA-4, potentially overcoming tumor-induced immunosuppression. Combination therapies integrate ICIs with proteasome inhibitors, immunomodulators, and monoclonal antibodies to enhance the anti-tumor immune response. Additionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy has demonstrated effectiveness against Multiple Myeloma, particularly when coupled with ICIs to decrease resistance and relapse.
Challenges:
Although the efficacy of ICIs in treating Multiple Myeloma has been hindered by the complexity of the tumor microenvironment and immune evasion mechanisms, this challenge has led to the exploration of combination therapies. Potential side effects are still a big challenge for newly recognized ICIs and combination treatment.
Future directions:
Investigations of new immune checkpoints and the development of targeted therapies against these markers are in progress, creating possibilities for more personalized and effective treatment strategies. Continuous research and robust clinical trials are needed to comprehend the complex dynamics of the Multiple Myeloma microenvironment to develop revolutionary therapeutic targets.
AlbagoushSAShumwayCAzevedoAM. Multiple Myeloma. [Updated 2023 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534764/
3.
DhodapkarMV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood2016; 128: 2599–2606. PMC free article, PubMed].
4.
BummaNNagasakaMHemingwayG, et al.Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clin Lymphoma Myeloma Leuk2020; 20: 305–311. PubMed] [Reference list.
5.
ChesiMNardiniELimRS, et al.The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood1998; 92: 3025–34. [PubMed] [Reference list]
6.
MichelsTCPetersenKE. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician2017; 95: 373–383. PubMed, Google Scholar.
7.
PadalaSABarsoukABarsoukA, et al.Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel)2021; 9: 3. PMID: 33498356; PMCID: PMC7838784.
8.
RajkumarSV.Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol2022; 97: 1086–1107. Epub 2022 May 23. PMID: 35560063; PMCID: PMC9387011. S
9.
LiuZXuXLiuH, et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol2023; 12: 99.
10.
DoboszPDzieciątkowskiT. The Intriguing History of Cancer Immunotherapy. Front in Immunol2019; 10: 2965.
11.
McCarthyEF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. The Iowa Orthop J2006; 26: 154.
12.
BrunetJFDenizotFLucianiMF, et al.A new member of the immunoglobulin superfamily—CTLA-4. Nature1987; 328: 267–270.
13.
AllisonJPMcintyreBWBlochD. The tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J of Immunol (Baltimore, Md.: 1950)1982; 129: 2293–2300.
AzourySCStraughanDMShuklaV. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. Curr Cancer Drug Targets2015; 15: 452–462.
16.
CoitDGThompsonJAAlgaziA, et al.NCCN guidelines insights: melanoma, version 3.2016. Journal of the Natl Compr Cancer Netw2016; 14: 945–958.
17.
HamidOPuzanovIDummerR, et al.Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer2017; 86: 37–45.
WeberJSO'DaySUrbaW, et al.Phase I/II study of ipilimumab for patients with metastatic melanoma. J Of Clin Oncol : Off J Of The Am Soc of Clin Oncol2008; 26: 5950–5956.
20.
HodiFSO'daySJMcDermottDF, et al.Improved survival with ipilimumab in patients with metastatic melanoma. New England J of Med2010; 363: 711–723.
21.
LangerLFClayTMMorseMA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opinion On Biol Therapy2007; 7: 1245–1256.
22.
HamidORobertCDaudA, et al.Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England J Of Med2013; 369: 134–144.
23.
BeckKEBlansfieldJATranKQ, et al.Enterocolitis in patients with cancer after antibody blockade of cytotoxic Tlymphocyte-associated antigen 4. J Clin Oncol2006; 24: 2283–2289.
24.
BlansfieldJABeckKATranK, et al.Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother2005; 28: 593–598.
25.
SandersonKScotlandRLeeP, et al.Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol2005; 23: 741–750.
26.
DarnellEPMooradianMJBaruchEN, et al.Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep2020; 22: 39.
27.
FajeATLawrenceDFlahertyK, et al.High-dose glucocorticoids for the treatment of ipilimumab induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer2018; 124: 3706–14.
28.
CollinsAVBrodieDWGilbertRJ, et al.The interaction properties of costimulatory molecules revisited. Immunity2002; 17: 201–210.
29.
OlssonCRiesbeckKDohlstenM,et al.CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J Of Biol Chem1999; 274: 14400–14405.
30.
KarabonLPawlak-AdamskaETomkiewiczA, et al.Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res : POR2012; 18: 219–226.
31.
ZhengCHuangDLiuL, et al.Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. British J of Haematol2001; 112: 216–218.
32.
ChungDJPronschinskeKBShyerJA, et al.T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunol Res2016; 4: 61–71.
33.
LiuZMiFHanM, et al.Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. Clin Exp Immunol2021; 205: 53–62.
34.
MonneyLSabatosCAGagliaJL, et al.Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature2002; 415: 536–541.
35.
LiuZYDengLJiaY, et al.CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma. Clin Transl Med2022; 12: e861.
36.
NingZLiuKXiongH. Roles of BTLA in Immunity and Immune Disorders. Front In Immunol2021; 12: 654960.
37.
SehgalKDasRZhangL, et al.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood2015; 125: 4042–4051.
38.
HuangSZhaoYLiaoP, et al.Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma. Front In Oncol2022; 12: 1014904.
39.
MutsaersPBalciogluHEKuiperR, et al.V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. Cancers2021; 13: 2219.
40.
HoteitRBazarbachiAAntarA, et al.KIR genotype distribution among patients with multiple myeloma: Higher prevalence of KIR 2DS4 and KIR 2DS5 genes. Meta Gene2014; 2: 730–736.
41.
GabrielIHSergeantRSzydloR, et al.Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood2010; 116: 2033–2039.
42.
JiangZBWangWJXuC, et al.Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett2021; 515: 36–48.
43.
SellamLSZappasodiRChettibiF, et al.Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Arch Of Biochem Biophys2020; 690: 108479.
44.
ShahUAMailankodyS. Emerging immunotherapies in multiple myeloma. BMJ (Clinical Research ed.)2020; 370: m3176.
45.
AlkharabshehOTriselZBadamiS, et al.Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises. Cancers2021; 14: 113.
46.
RubioMTDhuyserANguyenS. Role and Modulation of NK Cells in Multiple Myeloma. Hemato2021; 2: 167–181.
47.
Van HallTAndréPHorowitzA, et al.Monalizumab: inhibiting the novel immune checkpoint NKG2A. J For Immunotherapy Of Cancer2019; 7: 1–8.
48.
TognarelliSWirschingSvon MetzlerI, et al.Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma. Front In Immunol2018; 9: 2743.
49.
BonannoGMariottiAProcoliA, et al.Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Of Transl Med2012; 10: 247.
50.
RayASongYDuT, et al.Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple. Myeloma Leukemia2020; 34: 567–577.
51.
YonezawaADuttSChesterC, et al.Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res : an Off J of the Am Assoc for Cancer Res2015; 21: 3113–3120.
52.
JungSHLeeHJVoMC, et al.Immunotherapy for the treatment of multiple myeloma. Crit Rev In Oncol/Hematol2017; 111: 87–93.
53.
Hartley-BrownMChittyDThakurR. Monoclonal Antibodies in Myeloma: Optimizing Targeted Therapy. Cancer Journal (Sudbury, Mass.)2021; 27: 222–230.
54.
LonialSVijRHarousseauJL, et al.Elotuzumab In combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Of Clin Oncol : Off J of the Am Soc of Clin Oncol2012; 30: 1953–1959.
55.
LonialSDimopoulosMPalumboA, ELOQUENT-2 Investigators,. et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. The New England J Of Med2015; 373: 621–631.
56.
JakubowiakAJBensonDMBensingerW, et al.Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Of Clin Oncol: Off J Of The Am Soc of Clin Oncol2012; 30: 1960–1965.
57.
JakubowiakAOffidaniMPégourieB, et al.Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood2016; 127: 2833–2840.
58.
LokhorstHMPlesnerTLaubachJP, et al.Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. The New England J Of Med2015; 373: 1207–1219.
59.
LonialSWeissBMUsmaniSZ, et al.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (London, England)2016; 387: 1551–1560.
60.
PtaDTreonSPShimaY, et al.Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia2001; 15: 1950–1961.
61.
LiSPalRMonaghanSA, et al.IMiD immunomodulatory compounds block C/EBPbeta translation through eIF4E down-regulation resulting in inhibition of MM. Blood2011; 117: 5157–5165.
62.
MitsiadesNMitsiadesCSPoulakiV, et al.Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood2002; 99: 4525–4530.
63.
ShafferALEmreNCLamyL, et al.IRF4 addiction in multiple myeloma. Nature2008; 454: 226–231.
64.
QuachHRitchieDStewartAK, et al.Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia2010; 24: 22–32.
65.
LuptakovaKRosenblattJGlotzbeckerB, et al.Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother2013; 62: 39–49.
66.
ItoTAndoHSuzukiT, et al.Identification of a primary target of thalidomide teratogenicity. Science2010; 32: 1345–1350.
67.
LeeJZhouP. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell2007; 26: 775–780.
68.
BadrosA, et al.Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood2017; 130: 1189–1197.
69.
OcioEM, et al.Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses. J of Clin Oncol2017; 35: 8015–8015.
70.
MateosM-V, et al.A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183. J of Clin Oncol2018; 36: 8021–8021.
71.
KraussAC, et al.FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response. J of Clin Oncol JCO (2018); 36: 8008–8008.
72.
UsmaniSZSchjesvoldFOriolA, et al.Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol2019; 6: e448–58.
73.
PiankoMJ, et al.Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leuk Lymphoma2018; 59: 221–224.
74.
MateosMVBlacklockHSchjesvoldF, et al.Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol2019; 6: e459–69.
75.
ItoS. Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers2020; 12: 265.
76.
KegyesDGuleiDDrulaR, et al.Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Reviews2023; 61: 101100.
77.
FramptonAESivakumarS. A new combination immunotherapy in advanced melanoma. New England J of Med2022; 386: 91–92.
78.
HodiFSLawrenceDLezcanoC, et al.Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res2014; 2: 632–642.
79.
WuXLiJConnollyEM, et al.Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes. Cancer Immunol Res2017; 5: 446–454.
80.
VafaeiSZekiyAOKhanamirRA, et al.Combination therapy with immune checkpoint inhibitors (ICIs): A new frontier. Cancer Cell International2022; 22: 2.
81.
HodiFSChesneyJPavlickAC, et al.Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicenter, randomized, controlled, phase 2 trial. The Lancet Oncology2016; 17: 1558–1568.
82.
JuneCHO’ConnorRSKawalekarOU, et al.CAR T cell immunotherapy for human cancer.
83.
SadelainMRivièreIBrentjensR. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer2003; 3: 35–45.
84.
MausMVLevineBL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist2016; 21: 608–17.
85.
LaabiYGrasMPBrouetJC, et al.The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res1994; 22: 1147–1154.
86.
SmirnovaASAndrade-OliveiraVGerbase-DeLimaM. Identification of new splice variants of the genes BAFF and BCMA. Mol Immunol2008; 45: 1179–1183.
87.
LeeLBoundsDPatersonJ, et al.Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol2016; 174: 911–922.
RyanMCHeringMPeckhamD, et al.Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther2007; 6: 3009–3018.
91.
AliSAShiVMaricI, et al.T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood2016; 128: 1688–700.
92.
BrudnoJNMaricIHartmanSD, et al.T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol2018; 36: 2267–80.
93.
HasegawaKHosenN. Chimeric antigen receptor T cell therapy for multiple myeloma. Inflamm Regen2019; 39: 10.
94.
LevinAShahNN. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Am J Hematol2019; 94: S18–S23.
95.
NeelapuSSTummalaSKebriaeiP, et al.Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol2018; 15: 47–62.
96.
ZhaoWHLiuJWangBY, et al.A phase 1, open-label study of LCAR-B38 M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol2018; 11: 141.
97.
CohenADGarfallALStadtmauerEA, et al.B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest2019; 129; 2210–21.
98.
RajeNBerdejaJLinY, et al.Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med2019; 380: 1726–37.
99.
SantomassoBDParkJHSalloumD, et al.Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov2018; 8: 958–71.
100.
MaudeSLLaetschTWBuechnerJ, et al.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med2018; 378: 439–48.
101.
ParkJHRivièreIGonenM, et al.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med2018; 378: 449–59.
102.
GustJHayKAHanafiLA, et al.Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov2017; 7: 1404–19.
103.
DinarelloCASimonAvan der MeerJWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discovery2012; 11: 633–52.
104.
JatianiSSAlemanAMadduriD, et al.Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. Clin Lymphoma Myeloma Leuk. 2020;20:632–6 e631.
105.
GiavridisTvan der StegenSJCEyquemJ, et al.CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated.
106.
PieriniSGabbasovRGabitovaL, et al.Abstract 63: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models. Cancer Res2021; 81: 63.
107.
RuppLJSchumannKRoybalKT, et al.CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep2017; 7: 737.
108.
CherkasskyLMorelloAVillena-VargasJ, et al.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest2016; 126: 3130–44.
109.
YoonDHOsbornMJTolarJ,et al.Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. Int J Mol Sci2018; 19: 340.
110.
RafiqSYekuOOJacksonHJ, et al.Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol2018; 36: 847–56.
111.
GordonSRMauteRLDulkenBW, et al.PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature2017; 545: 495–9.
112.
GrosserRCherkasskyLChintalaN, et al.Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell2019; 36: 471–482. PMID: 31715131; PMCID: PMC717153.
113.
SidanaSShahN. CAR T-cell therapy: is it prime time in myeloma?Hematology Am Soc Hematol Educ Program2019; 2019: 260–265.
114.
MoonEK, et al.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res2014; 20: 4262–4273.
115.
SongWZhangM. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol2020; 214: 108382.
116.
BeareAStockingerHZolaH,et al.Monoclonal antibodies to human cell surface antigens. Current Protocols In Immunology2008; Appendix 4: A.4A.1–A.4A.73.
117.
GuoHCruz-MunozMEWuN, et al.Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cellular Biol2015; 35: 41–51.
118.
SmithELHarringtonKStaehrM, et al.GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med2019; 11: eaau7746.
119.
SchönfeldKZuberCPinkasJ, et al.Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol2017; 10: 13.
120.
WhitemanKRJohnsonHAMayoMF, et al.Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. mAbs2014; 6: 556–566.
121.
JagannathSLaubachJWongE, et al.Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. British J Of Haematol2018; 182: 495–503.
122.
KimKPhelpsMA. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. Clinical Pharmacokinetics2023; 62: 789–806.
123.
NeumeisterPSchulzEPansyK, et al.Targeting the Microenvironment for Treating Multiple Myeloma. Int J Of Mol Sci2022; 23: 7627.
124.
AlardEButnariuABGrilloM, et al.Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers2020; 12: 1826.
